drugset / Trial / NCT00350857

The Young Adult and Pediatric Bipolar Study

NCT00350857

Phase 4 Completed 161 enrolled Validus Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.

Timeline

Start
2006-07
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbamazepine Small molecule

Indications